Mode
Text Size
Log in / Sign up
N/A N=218 Randomized Double-blind Treatment

Clinical Investigation of the Next Generation Intraocular Lens

Cataract

Enrolled (actual)
218
Serious AEs
4.6%
Results posted
Jun 2020
Primary outcome: Primary: Monocular, Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 Centimeter (cm) — 0.053; 0.370 logMAR — p=< 0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL (Device); Control Monofocal Intraocular Lens: TECNIS Monofocal IOL (Device)
Age
Adult, Older Adult · 22+ yrs
Sex
All
Sponsor
Johnson & Johnson Surgical Vision, Inc.
Primary completion
Jun 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Monocular, Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 Centimeter (cm)
0.053; 0.370 < 0.0001 sig
PRIMARY
Monocular Photopic Distance Corrected Depth of Focus Assessed by the Mean Defocus Curve
2.3; 0.8
SECONDARY
Monocular, Photopic Distance Corrected Near Visual Acuity (DCNVA) at 40 cm
0.151; 0.466 <0.0001 sig
SECONDARY
Overall Spectacle Wear
63.3; 7.6 <0.0001 sig

Summary

An investigational IOL designed to provide improved intermediate and near visual acuity and decreased spectacle wear was evaluated for safety and effectiveness in a six-month study.

Eligibility Criteria

Inclusion Criteria

  • Minimum 22 years of age
  • Bilateral cataracts for which posterior chamber IOL implantation has been planned
  • Corneal astigmatism:
  • Normal corneal topography
  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures and study visits
  • Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries
  • Ability to understand and respond to a questionnaire in English

Exclusion Criteria

  • Irregular corneal astigmatism
  • Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)
  • Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery, Including prophylactic peripheral iridotomies and peripheral laser retinal repairs
  • Poorly-controlled diabetes
  • Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes
  • Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial
  • Desire for monovision correction
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03500198). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search